🇺🇸 FDA
Patent

US 8552018

Substituted tricyclic compounds as protein kinase inhibitors

granted A61KA61K31/519A61K45/06

Quick answer

US patent 8552018 (Substituted tricyclic compounds as protein kinase inhibitors) held by Arizona Board of Regents on Behalf of the University of Arizona expires Mon Oct 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arizona Board of Regents on Behalf of the University of Arizona
Grant date
Tue Oct 08 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/519, A61K45/06, A61P, A61P35/00